Acorda Therapeutics initiated with "outperform" update
newratings.com - USA
... the data from the ongoing Phase III Fampridine-SR trial in 3Q06 is expected to have a positive impact on the company's share price. Acorda Therapeutics also ...

Acorda Up on MS Trial Enrollment
MSN Money - USA
Acorda shares rose 36 cents, or 5.9 percent, to $6.48 in afternoon trading on the ... primary endpoint of the Phase III trial is to see if Fampridine-SR improves ...

Tysabri poised for return to market
Pharmaceutical Business Review - USA
... Biogen Idec's Rituxan (rituximab) is another monoclonal antibody, while Acorda's Fampridine SR is a sustained release tablet that is in trials for both MS and ...

Acorda Therapeutics Reports Fourth Quarter and Full Year 2005 ...
Genetic Engineering News - Larchmont,NY,USA
... zanaflexcapsules.com. Acorda's lead clinical-stage product is Fampridine-SR, which is in a Phase 3 clinical trial for MS. The Company's ...
See all stories on this topic

Burbs: Patent infringement suit settled
The Journal News.com - Westchester,NY,USA
... Acorda Therapeutics Inc., a Hawthorne biopharmaceutical company that develops treatments to ... enrollment of its Phase 3 clinical trial of Fampridine-SR in ...

Acorda Therapeutics(R) Announces Completion of Enrollment in ...
Genetic Engineering News - Larchmont,NY,USA
... obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations ...

Acorda completes enrollment for phase III MS trial
Pharmaceutical Business Review - USA
By Staff Writer. Acorda Therapeutics has completed enrollment of its phase III clinical trial of Fampridine-SR in multiple sclerosis. ...

Biotech's Mid Caps Post Solid Gain in February
PR Newswire (press release) - New York,NY,USA
... dropping 3% below its opening price before rallying late February to close the month at $9.84, up 9%. Acorda, whose lead product candidate, Fampridine-SR, is ...

Acorda completes enrollment in MS trial
United Press International - USA
HAWTHORNE, NY, March 3 (UPI) -- Acorda Therapeutics said Friday it has completed enrollment in its phase 3 study of multiple-sclerosis drug Fampridine SR. ...